Clinical Trial Update: Cenobamate Open-Label Extension Study for YKP3089C025 [Phase 3]

View source ↗

Summary

Open-label extension study for cenobamate (YKP3089) in patients with primary generalized tonic-clonic seizures associated with idiopathic generalized epilepsy h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Tonic-clonic Seizures
• Idiopathic Generalized Epilepsy

Drugs mentioned

• Cenobamate (cenobamate)

Snippet

Sponsor: SK Life Science, Inc. | Conditions: Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy | Phase 3 | Status: COMPLETED